- Home
- CADL vs EDD Comparison
CADL vs EDD Comparison
Compare CADL & EDD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CADL
- EDD
- Stock Information
- Founded
- CADL 1999
- EDD 2007
- Country
- CADL United States
- EDD United States
- Employees
- CADL N/A
- EDD N/A
- Industry
- CADL Biotechnology: Pharmaceutical Preparations
- EDD Finance Companies
- Sector
- CADL Health Care
- EDD Finance
- Exchange
- CADL Nasdaq
- EDD Nasdaq
- Market Cap
- CADL 306.4M
- EDD 307.8M
- IPO Year
- CADL 2021
- EDD N/A
- Fundamental
- Price
- CADL $8.06
- EDD $4.82
- Analyst Decision
- CADL Strong Buy
- EDD
- Analyst Count
- CADL 4
- EDD 0
- Target Price
- CADL $21.00
- EDD N/A
- AVG Volume (30 Days)
- CADL 1.2M
- EDD 254.3K
- Earning Date
- CADL 03-13-2025
- EDD 01-01-0001
- Dividend Yield
- CADL N/A
- EDD 7.52%
- EPS Growth
- CADL N/A
- EDD N/A
- EPS
- CADL N/A
- EDD N/A
- Revenue
- CADL N/A
- EDD N/A
- Revenue This Year
- CADL N/A
- EDD N/A
- Revenue Next Year
- CADL N/A
- EDD N/A
- P/E Ratio
- CADL N/A
- EDD N/A
- Revenue Growth
- CADL N/A
- EDD N/A
- 52 Week Low
- CADL $1.40
- EDD $4.22
- 52 Week High
- CADL $14.60
- EDD $4.95
- Technical
- Relative Strength Index (RSI)
- CADL 45.77
- EDD 55.15
- Support Level
- CADL $8.33
- EDD $4.71
- Resistance Level
- CADL $9.08
- EDD $4.91
- Average True Range (ATR)
- CADL 0.59
- EDD 0.04
- MACD
- CADL -0.04
- EDD 0.00
- Stochastic Oscillator
- CADL 42.70
- EDD 52.50
About CADL Candel Therapeutics Inc.
Candel Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer. The company has established two clinical-stage viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.
About EDD Morgan Stanley Emerging Markets Domestic Debt Fund Inc.
Morgan Stanley Emerging Markets Domestic Debt Fund Inc is a closed-end management investment company. The company's primary investment objective is to seek a high level of current income, with a secondary investment objective of long-term capital appreciation. It seeks to achieve investment objectives by investing, under normal circumstances, at least 80% of its managed assets in emerging markets domestic debt. The fund's portfolio includes sovereign, quasi-sovereign, corporate bonds in emerging markets.